Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.18 | -$0.17 | -$0.18 |
Q2 2025 | 1 | -$0.17 | -$0.17 | -$0.17 |
Q3 2025 | 1 | -$0.15 | -$0.15 | -$0.15 |
Q4 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
Gain Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.17 earnings per share for the quarter, topping analysts' consensus estimates of $-0.23 by $0.06. The company had revenue of 0 for the quarter and had revenue of 55,180 for the year. Gain Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.71 diluted earnings per share) and currently has a price-to-earnings ratio of -3.12. Gain Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/14/2024 | Q3 2024 | -$0.23 | -$0.17 | 0.06 | $10,000 | $0 |
08/08/2024 | Q2 2024 | -$0.31 | -$0.42 | -0.11 | $400,000 | $0 |
05/14/2024 | Q1 2024 | -$0.30 | -$0.22 | 0.08 | N/A | $0 |
03/26/2024 | Q4 2023 | -$0.32 | -$0.29 | 0.03 | N/A | $64,800 |
11/14/2023 | Q3 2023 | -$0.47 | -$0.37 | 0.1 | $337,500 | $0 |
08/10/2023 | Q2 2023 | -$0.33 | -$0.62 | -0.29 | $1.01 M | $0 |
05/12/2023 | Q1 2023 | -$0.40 | -$0.43 | -0.03 | N/A | $55,180 |
03/23/2023 | Q4 2022 | -$0.37 | -$0.39 | -0.02 | N/A | $140,108 |
11/10/2022 | Q3 2022 | -$0.46 | -$0.38 | 0.08 | $51,500 | $0 |
08/08/2022 | Q2 2022 | -$0.35 | -$0.43 | -0.08 | $31,667 | $95,102 |
05/16/2022 | Q1 2022 | -$0.34 | -$0.28 | 0.06 | N/A | $45,006 |
03/25/2022 | Q4 2021 | N/A | -$0.32 | N/A | N/A | $36,341 |
11/12/2021 | Q3 2021 | -$0.34 | -$0.39 | -0.05 | $20,000 | $27,345 |
08/12/2021 | Q2 2021 | N/A | -$0.30 | N/A | N/A | $89,173 |
05/10/2021 | Q1 2021 | -$0.21 | -$0.50 | -0.29 | N/A | $5,269 |
12/31/2020 | Q4 2020 | N/A | -$0.15 | N/A | N/A | $9,139 |
09/29/2020 | Q3 2020 | N/A | -$0.30 | N/A | N/A | $6,696 |
06/29/2020 | Q2 2020 | N/A | -$0.20 | N/A | N/A | $6,373 |
03/30/2020 | Q1 2020 | N/A | -$0.22 | N/A | N/A | $6,673 |
12/30/2019 | Q4 2019 | N/A | -$0.32 | N/A | N/A | $0 |
Gain Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based offlast year's report dates.
In the previous quarter, Gain Therapeutics, Inc. (:GANX) reported $-0.17 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.23 by $0.06.
The conference call for Gain Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Gain Therapeutics, Inc.'s latest earnings report can be read online.
Gain Therapeutics, Inc. (:GANX) has a recorded annual revenue of $55,180.
Gain Therapeutics, Inc. (:GANX) has a recorded net income of $-22,267,520.Gain Therapeutics, Inc. has generated $-1.71 earnings per share over the last four quarters.
Gain Therapeutics, Inc. (:GANX) has a price-to-earnings ratio of -3.12 and price/earnings-to-growth ratio is -0.23.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED